6,231 Shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets bought a new position in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 6,231 shares of the company’s stock, valued at approximately $43,000.

A number of other hedge funds have also recently bought and sold shares of GLUE. Tower Research Capital LLC TRC grew its stake in shares of Monte Rosa Therapeutics by 192.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,443 shares of the company’s stock valued at $38,000 after buying an additional 3,584 shares during the period. Virtus ETF Advisers LLC purchased a new stake in shares of Monte Rosa Therapeutics during the 4th quarter valued at $63,000. Invesco Ltd. purchased a new stake in shares of Monte Rosa Therapeutics during the 4th quarter valued at $89,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Monte Rosa Therapeutics during the 4th quarter valued at $90,000. Finally, Janney Montgomery Scott LLC purchased a new stake in shares of Monte Rosa Therapeutics during the 4th quarter valued at $92,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Price Performance

Shares of Monte Rosa Therapeutics stock opened at $4.64 on Wednesday. The business has a 50-day moving average of $4.34 and a 200-day moving average of $6.00. The company has a market capitalization of $285.41 million, a PE ratio of -2.54 and a beta of 1.52. Monte Rosa Therapeutics, Inc. has a 1-year low of $3.21 and a 1-year high of $12.40.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its earnings results on Thursday, May 8th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.81. The business had revenue of $84.93 million for the quarter, compared to analyst estimates of $13.57 million. On average, equities analysts expect that Monte Rosa Therapeutics, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Wedbush restated an “outperform” rating and set a $17.00 target price (up previously from $15.00) on shares of Monte Rosa Therapeutics in a report on Thursday, March 20th. Wall Street Zen lowered shares of Monte Rosa Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 22nd. Lifesci Capital began coverage on shares of Monte Rosa Therapeutics in a report on Wednesday, March 12th. They set an “outperform” rating and a $19.00 target price on the stock. Finally, Wells Fargo & Company decreased their price objective on shares of Monte Rosa Therapeutics from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Friday, March 21st. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $15.50.

Insider Activity at Monte Rosa Therapeutics

In other news, Director Chandra P. Leo acquired 10,000 shares of the stock in a transaction that occurred on Monday, March 24th. The stock was purchased at an average cost of $5.84 per share, with a total value of $58,400.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at $58,400. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 6.90% of the stock is owned by corporate insiders.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.